FDA grants Priority Review for Genentech’s Enspryng sBLA for MOGAD

Genentech said the U.S. Food and Drug Administration granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for treatment of myelin oligodendrocyte glycoprotin-associated disease (MOGAD).